Appendix
← Clinical Reader
Internal Medicine

Bamlanivimab

Bamlanivimab is an investigational drug developed for COVID-19 pneumonia. It is in the class of neutralizing monoclonal antibodies. This activity illustrates the indications, action, and contraindications for bamlanivimab as a novel agent in the treatment and post-exposure prophylaxis of COVID-19. It will highlight the mechanism of action, adverse events, monitoring, and relevant interactions pertinent to the healthcare team in managing patients with COVID-19, especially in an ambulatory setting

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • due to the high frequency of the Omicron variant, bamlanivimab and etesevimab, administered together, are not currently authorized for use in any U.S. region because of markedly reduced activity against the Omicron variant.
  • Areas where resistance to combination or individual therapy for SARS-CoV-2 variants exceeds 5%
  • Hospitalized due to COVID-19 infection
  • Requiring oxygen therapy
  • Requiring increased oxygen supplementation due to COVID-19 compared to baseline need due to comorbidities unrelated to COVID-19
  • Patients with Direct SARS-CoV-2 Viral test positive results and within 10 days of symptom onset
  • Exposed to an individual infected with SARS-CoV-2 defined by close contact criteria as per Centers for Disease Control and Prevention (CDC) or at high risk for exposure in the same institutional setting due to the occurrence of SARS-CoV-2 in that setting, such as a nursing home or prisons.
  • CDC describes close contact with an infected individual as being within 6 feet for at least 15 minutes, direct physical contact, droplet exposure, or providing care at home to an infected individual.
  • Bamlanivimab is authorized by the FDA when administered as an infusion in combination with etesevimab.
  • Mild to moderate COVID-19, at higher risk of progression to severe disease, including hospitalization or death
  • Not fully vaccinated or not expected to have adequate response to complete vaccination.
  • The following patient population qualifies as high-risk individuals:
  • Age ≥ 65 years or <1 year
  • Body mass index (BMI): Adults - BMI > 25 kg/m2; age 12 to 17 years - BMI ≥ 85th percentile for age and sex
  • Pregnancy
  • Diabetes
  • Cardiovascular disease, including hypertension, congenital heart disease
  • Lung disease - moderate to severe asthma, chronic obstructive pulmonary disease (COPD), Interstitial lung disease (ILD), cystic fibrosis, and pulmonary hypertension
  • Chronic kidney disease
  • Neurodevelopmental disorders
  • Immunocompromised state including cancer, organ transplant, HIV, individuals on immunosuppressive treatment
  • Sickle cell disease
  • Dependence on medical-related technology, like tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19
  • The other neutralizing antibodies available are casirivimab and imdevimab, used in combination therapy.
  • The other novel agent in this class is sotrovimab.
  • There is no absolute contraindication for the use of bamlanivimab.
  • Human IgG1 antibodies can cross the placental barrier, so the drug has the potential to do the same.
  • The FDA recommends using the drug in pregnant women if the potential benefit outweighs the risk to both the mother and the fetus.
  • Bamlanivimab has a molecular weight of 146,000 Da. Because it is a very large protein, the amount of the drug in the milk is expected to be low.
  • There is no data available regarding the effect of bamlanivimab on breast milk production and breastfed infants .
  • The use of the drug should be considered on an individual basis.
  • Patients should be assessed at the infusion center before the infusion.
  • Those who meet the criteria for infusion should be observed for any hypersensitivity or infusion-related reaction mentioned above during the infusion time and at least 1-hour post-infusion.
  • Patients should also be advised to watch out for symptoms for at least 7 days post-infusion.
  • As bamlanivimab is not metabolized by cytochrome 450 enzymes or renally excreted, concomitant drug interactions are unlikely.
  • Emerging variants that are resistant to the combination drug—the combination drug does not have activity against the Omicron variant—can potentially cause treatment failure.
  • Updates regarding resistance trends and authorized use of combination therapy can be accessed via the U.S. Department of Health and Human Services and the CDC websites.
  • In case of overdose, supportive treatment is recommended, along with monitoring of vitals and clinical status.
  • FDA recommends reporting any serious adverse events considered potentially related to the infusion within 7 days from the onset of the event.
  • review
    Bamlanivimab. StatPearls [Internet] — Jishna Shrestha, Robin Sherchan — StatPearls Publishing, 2023

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov